Filing Flows › 10x Genomics (TXG) › Who owns the stock
Who owns 10x Genomics (TXG) stock
391 funds reported 10x Genomics (TXG) shares in their latest 13F filings, worth $5.1B in all. The largest holder is FMR LLC ($676M). Last quarter 174 funds added to their stakes and 159 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| FMR LLC | 17,629,266 | $676M | decrease | 2026-06-30 |
| BlackRock | 10,804,070 | $414M | increase | 2026-06-30 |
| ARK Investment Management LLC | 10,003,057 | $384M | decrease | 2026-06-30 |
| Vanguard Portfolio Management LLC | 6,982,492 | $268M | increase | 2026-06-30 |
| Vanguard Group | 13,017,914 | $212M | decrease | 2025-12-31 |
| Quantinno Capital Management LP | 5,469,698 | $210M | increase | 2026-06-30 |
| Vanguard Capital Management LLC | 5,082,594 | $195M | decrease | 2026-06-30 |
| Price T Rowe Associates | 4,539,007 | $174M | increase | 2026-06-30 |
| Sumitomo Mitsui Trust Group | 4,194,627 | $161M | decrease | 2026-06-30 |
| Nikko Asset Management Americas | 4,192,517 | $161M | decrease | 2026-06-30 |
| Morgan Stanley | 3,351,911 | $129M | increase | 2026-06-30 |
| Goldman Sachs Group | 3,148,859 | $121M | decrease | 2026-06-30 |
| Geode Capital Management, LLC | 3,082,790 | $118M | increase | 2026-06-30 |
| State Street | 2,801,437 | $107M | increase | 2026-06-30 |
| Citadel Advisors LLC | 2,779,213 | $107M | increase | 2026-06-30 |
10x Genomics' latest quarter
10x Genomics, Q3 2026: revenue $151M (+1% year over year), operating margin -10.7%, net loss $19.4M, operating cash flow $15.8M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most TXG stock?
By the latest 13F filings: FMR LLC ($676M); BlackRock ($414M); ARK Investment Management LLC ($384M); Vanguard Portfolio Management LLC ($268M); Vanguard Group ($212M).
What is the short interest in TXG?
12,732,231 shares were sold short at the 2026-10-15 settlement, -17.17% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.